{
    "clinical_study": {
        "@rank": "24928", 
        "arm_group": {
            "arm_group_label": "Patients with POAG or OHT", 
            "description": "Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice."
        }, 
        "brief_summary": {
            "textblock": "This study is a prospective, observational study of changing from any IOP-lowering treatment\n      to a prostaglandin analogue-containing IOP-lowering medication for patients with Primary\n      Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).  The decision to change medications\n      lies with the physician according to their standard practice."
        }, 
        "brief_title": "An Observational Study of Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) Who Switched IOP-lowering Treatments", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Glaucoma, Open-Angle", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Diagnosis of primary open angle glaucoma (POAG) or ocular hypertension (OHT)\n\n          -  Previously prescribed any IOP-lowering therapy which has been stopped and a new\n             prostaglandin analogue -containing IOP-lowering therapy started\n\n        Exclusion Criteria:\n\n          -  None"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "POAG or OHT"
            }
        }, 
        "enrollment": {
            "#text": "402", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01735214", 
            "org_study_id": "MAF/AGN/OPH/GLA/037"
        }, 
        "intervention": {
            "arm_group_label": "Patients with POAG or OHT", 
            "description": "Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.", 
            "intervention_name": "Prostaglandin Analogue -Containing IOP-Lowering Therapy", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Istanbul", 
                    "country": "Turkey"
                }
            }
        }, 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_groups": "1", 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Turkey: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline in Intraocular Pressure (IOP)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 12 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01735214"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Patient Assessment of Tolerability with New Treatment Using a 4-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Physician Assessment of Tolerability with New Treatment Using a 4-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Percentage of Patients Who Discontinue the Use of New Treatment Prior to 12 Weeks", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Percentage of Patients who Continue the New Treatment After 12 Weeks", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Physician Assessment of Adherence to New Treatment Using a 4-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Physician Assessment of Efficacy Using a 5-Point Scale", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Percentage of Patients Reaching Individual IOP Target After 12 Weeks", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }
        ], 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}